A Phase II Study of NK012 in Locally Advanced Non-Resectable and Metastatic Breast Cancer Patients With Triple Negative Phenotype
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2015
At a glance
- Drugs NK 012 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Nippon Kayaku
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 19 Mar 2013 Planned end date changed from 1 Nov 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.